Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven G Hughes

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
The New England Journal of Medicine|December 4, 2014
Targeting APOC3 in the familial chylomicronemia syndromeDaniel Gaudet, Diane Brisson, Karine Tremblay, et al.
Nucleic Acid Therapeutics|February 2, 2017
The Effects of 2'-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical TrialsStanley T Crooke, Brenda F Baker, Joseph L Witztum, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 30, 2016
Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotidesElizabeth J Ackermann, Shuling Guo, Merrill D Benson, et al.
Lancet (London, England)|July 27, 2015
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 studySotirios Tsimikas, Nicholas J Viney, Steven G Hughes, et al.
Diabetes Care|June 9, 2016
Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 DiabetesAndres Digenio, Richard L Dunbar, Veronica J Alexander, et al.
The New England Journal of Medicine|July 30, 2015
Antisense Inhibition of Apolipoprotein C-III in Patients with HypertriglyceridemiaDaniel Gaudet, Veronica J Alexander, Brenda F Baker, et al.
Nucleic Acid Therapeutics|March 1, 2019
IONIS-PKK<sub>Rx</sub> a Novel Antisense Inhibitor of Prekallikrein and Bradykinin ProductionJason D Ferrone, Gourab Bhattacharjee, Alexey S Revenko, et al.
Lancet (London, England)|September 26, 2016
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trialsNicholas J Viney, Julian C van Capelleveen, Richard S Geary, et al.
Nucleic Acid Therapeutics|February 12, 2020
Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated ThrombocytopeniaPadmaKumar Narayanan, Brian R Curtis, Lijiang Shen, et al.
The New England Journal of Medicine|August 8, 2019
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia SyndromeJoseph L Witztum, Daniel Gaudet, Steven D Freedman, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
The New England Journal of Medicine|December 4, 2014
Targeting APOC3 in the familial chylomicronemia syndromeDaniel Gaudet, Diane Brisson, Karine Tremblay, et al.
Nucleic Acid Therapeutics|February 2, 2017
The Effects of 2'-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical TrialsStanley T Crooke, Brenda F Baker, Joseph L Witztum, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 30, 2016
Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotidesElizabeth J Ackermann, Shuling Guo, Merrill D Benson, et al.
Lancet (London, England)|July 27, 2015
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 studySotirios Tsimikas, Nicholas J Viney, Steven G Hughes, et al.
Diabetes Care|June 9, 2016
Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 DiabetesAndres Digenio, Richard L Dunbar, Veronica J Alexander, et al.
The New England Journal of Medicine|July 30, 2015
Antisense Inhibition of Apolipoprotein C-III in Patients with HypertriglyceridemiaDaniel Gaudet, Veronica J Alexander, Brenda F Baker, et al.
Nucleic Acid Therapeutics|March 1, 2019
IONIS-PKK<sub>Rx</sub> a Novel Antisense Inhibitor of Prekallikrein and Bradykinin ProductionJason D Ferrone, Gourab Bhattacharjee, Alexey S Revenko, et al.
Lancet (London, England)|September 26, 2016
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trialsNicholas J Viney, Julian C van Capelleveen, Richard S Geary, et al.
Nucleic Acid Therapeutics|February 12, 2020
Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated ThrombocytopeniaPadmaKumar Narayanan, Brian R Curtis, Lijiang Shen, et al.
The New England Journal of Medicine|August 8, 2019
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia SyndromeJoseph L Witztum, Daniel Gaudet, Steven D Freedman, et al.
Pageof 4